VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?

A sharp rally in Viking Therapeutics (VKTX) has put its obesity drug VK2735 back in the spotlight, with the stock pulling ahead of Eli Lilly (LLY) and Novo Nordisk (NVO) as investors weigh whether Viking could one day draw patients away from Wegovy and Zepbound.VKTX stock jumped 36% on Tuesday, log…